Thomas Shrader
Stock Analyst at BTIG
(1.49)
# 3,336
Out of 4,935 analysts
49
Total ratings
36.59%
Success rate
-7.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Downgrades: Neutral | n/a | $105.40 | - | 4 | Jul 10, 2025 | |
| INMB INmune Bio | Downgrades: Neutral | n/a | $2.79 | - | 3 | Jul 1, 2025 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $5.17 | +74.08% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $0.51 | +682.01% | 3 | Mar 24, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $30.01 | +433.16% | 4 | Feb 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $11.98 | +242.24% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.46 | +242.47% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.37 | - | 3 | Sep 4, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.10 | +280.95% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.55 | +1,354.28% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.57 | +1,212.91% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $15.23 | +57.58% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $2.37 | +195.36% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.10 | +145.90% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.38 | +3,321.95% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.49 | +571.14% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.42 | +1,449.30% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.68 | +2,935.71% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.34 | +583.76% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.22 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.23 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $9.02 | +543.02% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.30 | +130.77% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $127.75 | +170.84% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.59 | - | 1 | Jun 30, 2017 |
Verona Pharma
Jul 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $105.40
Upside: -
INmune Bio
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.79
Upside: -
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.17
Upside: +74.08%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.51
Upside: +682.01%
Vaxcyte
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $30.01
Upside: +433.16%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $11.98
Upside: +242.24%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.46
Upside: +242.47%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.37
Upside: -
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.10
Upside: +280.95%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.55
Upside: +1,354.28%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.57
Upside: +1,212.91%
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $15.23
Upside: +57.58%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.37
Upside: +195.36%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.10
Upside: +145.90%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.38
Upside: +3,321.95%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.49
Upside: +571.14%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.42
Upside: +1,449.30%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.68
Upside: +2,935.71%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.34
Upside: +583.76%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.22
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.23
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $9.02
Upside: +543.02%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.30
Upside: +130.77%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $127.75
Upside: +170.84%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.59
Upside: -